Document Detail

Ocular carteolol: a review of its use in the management of glaucoma and ocular hypertension.
MedLine Citation:
PMID:  17571916     Owner:  NLM     Status:  MEDLINE    
Ocular carteolol (Mikelan), Teoptic, Ocupress) is a nonselective beta-adrenoceptor antagonist with intrinsic sympathomimetic activity (ISA). Ocular carteolol effectively reduces intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OH). Twice-daily administration of standard carteolol has generally similar IOP-lowering efficacy to other ocular beta-adrenoceptor antagonists such as timolol, betaxolol and metipranolol in patients with OAG or OH. In addition, long-term treatment with carteolol has similar efficacy to timolol and betaxolol in terms of reducing IOP and maintaining visual fields in patients with newly diagnosed primary OAG (POAG). The new long-acting formulation of once-daily carteolol has equivalent efficacy to the standard formulation of carteolol administered twice daily in patients with OAG or OH. Both the standard and long-acting formulations of ocular carteolol are generally well tolerated in terms of topical adverse effects involving the eyes or systemic adverse effects involving the cardiovascular system. Thus, twice-daily carteolol is a well established option in the treatment of glaucoma and OH, and the new once-daily formulation of long-acting carteolol offers similar efficacy and tolerability with a potential for improved patient adherence.
Sheridan Henness; Tracy Swainston Harrison; Gillian M Keating
Related Documents :
812836 - The effect of d-isoproterenol on intraocular pressure of the rabbit, monkey, and man.
3561946 - Effect of timolol on optic nerve head autoregulation.
22372776 - Within-visit variability of blood pressure and all-cause and cardiovascular mortality a...
8160986 - Trabecular outflow facility and formation rate of aqueous humor during intravenous coca...
6321816 - Vasopressin as a possible contributor to hypertension.
22362566 - High gas pressure: an innovative method for the inactivation of dried bacterial spores.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Drugs & aging     Volume:  24     ISSN:  1170-229X     ISO Abbreviation:  Drugs Aging     Publication Date:  2007  
Date Detail:
Created Date:  2007-06-18     Completed Date:  2007-08-16     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9102074     Medline TA:  Drugs Aging     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  509-28     Citation Subset:  IM    
Wolters Kluwer Health | Adis, Auckland, New Zealand.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic beta-Antagonists / adverse effects,  therapeutic use
Carteolol / adverse effects,  therapeutic use*
Clinical Trials as Topic
Glaucoma / drug therapy*,  physiopathology
Instillation, Drug
Middle Aged
Ocular Hypertension / drug therapy*
Treatment Outcome
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 51781-06-7/Carteolol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Tolerability of an equimolar mix of nitrous oxide and oxygen during painful procedures in very elder...
Next Document:  From morphology to neural information: the electric sense of the skate.